Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Zantac 25

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

79 API Suppliers, 30 USDMF, 14 CEP/COS, 2 JDMF, 4 EU WC, 45 KDMF, 7 NDC API, 6 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

184 FDF Dossiers, 121 FDA Orange Book, 35 Europe, 9 Canada, 19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 25MG BASE/ML, TABLET;ORAL - EQ 75MG BASE, TABLET;ORAL - EQ 150MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 4 Rochem International Inc, 8 SPI Pharma, 11 DKSH, 1 Pharm-RX Chemical, 3 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 5 Kirsch Pharma, 4 ACG Worldwide, 13 Actylis, 1 Aeon Procare, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 16 BASF, 1 Bioplus Life Sciences, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 3 Finar, 9 Gangwal Chemicals, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 19 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 32 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

59 Fillers, Diluents & Binders, 45 Coating Systems & Additives, 27 Thickeners and Stabilizers, 26 Disintegrants & Superdisintegrants, 24 Parenteral, 22 Film Formers & Plasticizers, 22 Granulation, 22 Taste Masking, 22 Direct Compression, 21 Controlled & Modified Release, 20 Solubilizers, 19 Topical, 16 Lubricants & Glidants, 14 Co-Processed Excipients, 9 Chewable & Orodispersible Aids, 9 Empty Capsules, 8 Emulsifying Agents, 7 API Stability Enhancers, 7 Rheology Modifiers, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

120 News #PharmaBuzz

120 News #PharmaBuzz

GLOBAL SALES INFORMATION

7 Regulatory FDF Prices, 3 Annual Reports

MARKET PLACE

20 APIs

20 APIs

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

4 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 2 JP, 1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	GSK	United Kingdom	GlaxoSmithKline Inc.	20050831-35-B-97-05	ranitidine hydrochloride	2003-08-31	Glaxo Wellcome Manufacturing Pte Ltd	Singapore	1 Pioneer Sector 1, Singapore 628413
29/11/2025	Kyongbo Pharmaceutical Co., Ltd	South Korea	Kyungbo Pharmaceutical Co., Ltd.	20050831-35-B-96-04	ranitidine hydrochloride	2005-08-31	Kyungbo Pharmaceutical Co., Ltd.	South Korea	174 Silok-ro, Asan-si, Chungcheongnam-do

Zantac 25

Zantac 25

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

79 API Suppliers

30 USDMF

14 CEP/COS

2 JDMF

4 EU WC

45 KDMF

7 NDC API

6 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

184 FDF Dossiers

121 FDA Orange Book

35 Europe

9 Canada

19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 25MG BASE/ML

TABLET;ORAL - EQ 75MG BASE

TABLET;ORAL - EQ 150MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI

4 Rochem International Inc

8 SPI Pharma

11 DKSH

1 Pharm-RX Chemical

3 Boai NKY Pharmaceuticals Ltd

8 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

5 Kirsch Pharma

4 ACG Worldwide

13 Actylis

1 Aeon Procare

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

16 BASF

1 Bioplus Life Sciences

1 Clariant

10 Corel Pharma Chem

6 DFE Pharma

1 Esteem Industries

3 Finar

9 Gangwal Chemicals

4 Ideal Cures

4 Ingredion Pharma Solutions

19 Kerry

3 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

10 Microlex e.U

1 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

1 Novo Excipients

2 Pharmatrans-Sanaq

7 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

32 Roquette

13 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

11 Sigachi Industries

4 Silverline Chemicals

2 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

TABLET;ORAL - EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 300MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons